Munters to present Q3 interim report via webcast and call
Bitget2026/10/09 08:00Munters schedules release of its Q3 2026 interim report for Oct. 23 at 07:30 CEST. Webcast presentation of the Q3 report set for Oct. 23 at 09:00 CEST; link: https://munters.events.inderes.com/q3-report-2026. Telephone conference on the Q3 report also planned for Oct. 23 at 09:00 CEST; registration: https://events.inderes.com/munters/q3-report-2026/dial-in. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Munters Group AB published the original content used to generate this news brief via Cision (Ref. ID: 202610090400BITN____UKPR__EN_20261007-BIT-0123-0) on October 09, 2026, and is solely responsible for the information contained therein.
- Munters schedules release of its Q3 2026 interim report for Oct. 23 at 07:30 CEST.
- Webcast presentation of the Q3 report set for Oct. 23 at 09:00 CEST; link: https://munters.events.inderes.com/q3-report-2026.
- Telephone conference on the Q3 report also planned for Oct. 23 at 09:00 CEST; registration: https://events.inderes.com/munters/q3-report-2026/dial-in.
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
The US FDA requires semaglutide, tirzepatide, and other GLP-1 drugs to include new warnings about the risk of eye disease.
NAION is an eye disease that can cause sudden, painless loss of vision, with some patients potentially experiencing permanent visual impairment. The drugs involved include products from Eli Lilly and Novo Nordisk. According to analysts at Citi, the incidence of NAION is relatively low, and given the significant benefits of GLP-1 drugs in weight control and blood sugar management, the actual impact on prescription behavior is expected to be limited. On Monday, the stock prices of Eli Lilly and Novo Nordisk increased, with the news not causing any significant impact on their share prices.
CleanSpark presents fully funded Sandersville project in investor presentation

Forge Nano completes acquisition of HzO